You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

LGMD2B/R2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Limb Girdle Muscular Dystrophy Trial in Columbus (SRP-6004)

Enrolling by invitation
  • Limb Girdle Muscular Dystrophy
  • SRP-6004
  • Columbus, Ohio
    Nationwide Children's Hospital
Jun 7, 2023

Long-Term Development of Muscular Dystrophy Outcome Assessments

Not yet recruiting
  • LGMD1A
  • +33 more
    • Richmond, Virginia
      Virginia Commonwealth University
    Aug 3, 2023

    Trial Readiness and Endpoint Assessment in LGMD R1

    Not yet recruiting
    • Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A
    • +3 more
      • Richmond, Virginia
        Virginia Commonwealth University
      Jan 10, 2023

      LGMD2E/R4, LGMD2D/R3, and LGMD2C/R5, = 4 Years of Age, Who Are

      Recruiting
      • Limb-girdle Muscular Dystrophy
        • Phoenix, Arizona
        • +14 more
        Aug 23, 2022

        Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I Trial (LION-101 dose level 1, LION-101 dose level

        Not yet recruiting
        • Limb Girdle Muscular Dystrophy
        • +8 more
        • LION-101 dose level 1
        • +2 more
        • (no location specified)
        Feb 17, 2022

        Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) Trial in Gainesville (BBP-418 (ribitol), Placebo)

        Not yet recruiting
        • Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
        • BBP-418 (ribitol)
        • Placebo
        • Gainesville, Florida
          University of Florida
        Mar 16, 2023

        Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

        Not yet recruiting
        • Relapsed/Refractory Marginal Zone Lymphoma
        • Guangzhou, Guangdong, China
        • +10 more
        Oct 8, 2023

        Limb-Girdle Muscular Dystrophy, Type 2E Trial in Columbus (SRP-9003)

        Active, not recruiting
        • Limb-Girdle Muscular Dystrophy, Type 2E
        • SRP-9003
        • Columbus, Ohio
          Nationwide Children's Hospital
        Sep 28, 2022

        LGMD2C Trial (ATA-200)

        Not yet recruiting
        • LGMD2C
        • ATA-200
        • (no location specified)
        Aug 1, 2023

        Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy

        Recruiting
        • Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency
        • +51 more
          • Lakewood, California
            Congenital Muscle Disease International Registry (www.cmdir.org)
          Aug 3, 2021

          Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

          Not yet recruiting
          • Metastatic Castration-resistant Prostate Cancer (mCRPC)
          • (no location specified)
          Aug 8, 2023

          Healthy Volunteers Trial in Seoul (NVP-1805, NVP-1805-R1 and NVP-1805-R2)

          Active, not recruiting
          • Healthy Volunteers
          • Seoul, Korea, Republic of
            H Plus Yangji Hospita
          Jan 5, 2023

          Biomarker Development in LGMD2i

          Active, not recruiting
          • Muscular Dystrophies
          • Limb Girdle Muscular Dystrophy
            • Irvine, California
            • +10 more
            Feb 18, 2022

            B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

            Not yet recruiting
            • B Precursor Acute Lymphoblastic Leukemia
            • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
            • (no location specified)
            Sep 25, 2023

            LGMD2I Trial in Richmond (BBP-418)

            Active, not recruiting
            • LGMD2I
            • Richmond, Virginia
              Virginia Commonwealth University
            Dec 17, 2021

            Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

            Not yet recruiting
            • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
            • (no location specified)
            Sep 5, 2023

            Dysferlinopathy, Miyoshi Myopathy, LGMDR2 Trial in Moscow

            Enrolling by invitation
            • Dysferlinopathy
            • +3 more
              • Moscow, Russian Federation
                Human Stem Cells Institute
              Jul 25, 2022

              LGMD Trial (GenPHSat injection (Safety), GenPHSat injection (Efficacy), Muscle Biopsy (Safety))

              Not yet recruiting
              • LGMD
              • GenPHSat injection (Safety)
              • +2 more
              • (no location specified)
              Oct 20, 2022

              Healthy Trial in Seoul (DA-5218, DA-5218-R1 + DA-5218-R2 + DA-5218-R3)

              Not yet recruiting
              • Healthy
              • DA-5218
              • DA-5218-R1 + DA-5218-R2 + DA-5218-R3
              • Seoul, Korea, Republic of
                Bumin Hospital
              Jul 4, 2022

              Pneumococcal Vaccines Trial in Canada (IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C)

              Not yet recruiting
              • Pneumococcal Vaccines
              • IVT PCV-25 Formulation A
              • +3 more
              • Vancouver, British Columbia, Canada
              • +3 more
              Oct 10, 2023

              Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

              Not yet recruiting
              • Advanced Diffuse Large B-Cell Lymphoma
              • +2 more
              • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
              • Radiotherapy beyond standard R-CHOP Chemotherapy
              • (no location specified)
              May 24, 2023

              HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

              Active, not recruiting
              • HER2-positive Breast Cancer
              • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
              • Chengdu, Sichuan, China
                West China Hospital of Sichuan University
              Jan 30, 2023

              Healthy Trial in Seoul (DA-5211, DA-5211-R1 + DA-5211-R2)

              Completed
              • Healthy
              • Seoul, Korea, Republic of
                Bumin Hospital
              Jun 2, 2022

              Lymphoma, Large B-Cell, Diffuse Trial in Worldwide (Durvalumab, Rituximab, Doxorubicin)

              Completed
              Has Results
              • Lymphoma, Large B-Cell, Diffuse
              • Gilbert, Arizona
              • +18 more
              Aug 19, 2022

              Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in Valhalla (DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B)

              Recruiting
              • Non-hodgkin Lymphoma
              • Hodgkin Lymphoma
              • DOC Group B
              • +16 more
              • Valhalla, New York
                New York Medical College
              Jun 9, 2022